In this study, we revealed that blocking the SREBP-regulated metabolic pathways by fatostatin had a better inhibitory on the proliferation of PCa cells with high levels of mutant p53 (PC-3 R248W and DU145) than cells with null (PC-3 EV) or low levels of mutant p53 (DU145 shp53). The gene discussed is TP53; the disease is posterior cortical atrophy.